| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9775851 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9655907 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9433630 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9877974 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US10179137 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9439911 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
| US9364485 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
Sernivo is owned by Primus Pharms.
Sernivo contains Betamethasone Dipropionate.
Sernivo has a total of 7 drug patents out of which 0 drug patents have expired.
Sernivo was authorised for market use on 05 February, 2016.
Sernivo is available in spray;topical dosage forms.
Sernivo can be used as treatment of plaque psoriasis.
The generics of Sernivo are possible to be released after 31 August, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 05, 2019 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 05 February, 2016
Treatment: Treatment of plaque psoriasis
Dosage: SPRAY;TOPICAL
How can I launch a generic of SERNIVO before it's drug patent expiration?
More Information on Dosage
SERNIVO family patents
